These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 33511572)

  • 1. COVID-19 Adaptations in the Care of Patients with Opioid Use Disorder: a Survey of California Primary Care Clinics.
    Caton L; Cheng H; Garneau HC; Fisher T; Harris-Mills B; Hurley B; Newman S; McGovern MP
    J Gen Intern Med; 2021 Apr; 36(4):998-1005. PubMed ID: 33511572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptations to Opioid Use Disorder Care During the COVID-19 Pandemic: A National Survey of Prescribers.
    Sung ML; Black AC; Blevins D; Henry BF; Cates-Wessel K; Dawes MA; Drexler K; Hagle H; Molfenter T; Levin FR; Becker WC; Edelman EJ
    J Addict Med; 2022 Sep-Oct 01; 16(5):505-513. PubMed ID: 35020698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
    Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
    J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
    Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
    JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sharp decline in hospital and emergency department initiated buprenorphine for opioid use disorder during COVID-19 state of emergency in California.
    Herring AA; Kalmin M; Speener M; Goodman-Meza D; Snyder H; Campbell A; Moulin A; Shoptaw S
    J Subst Abuse Treat; 2021 Apr; 123():108260. PubMed ID: 33612194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
    Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
    Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV; Levin FR; Reilly MP; El-Bassel N
    J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
    Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic.
    Cunningham CO; Khalid L; Deng Y; Torres-Lockhart K; Masyukova M; Thomas S; Zhang C; Lu T
    J Subst Abuse Treat; 2022 Apr; 135():108641. PubMed ID: 34863608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH; Cales SC; Shreffler J; Huecker MR
    J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.
    Krawczyk N; Fawole A; Yang J; Tofighi B
    Addict Sci Clin Pract; 2021 Nov; 16(1):68. PubMed ID: 34774106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine.
    Du CX; Shi J; Tetrault JM; Madden LM; Barry DT
    Fam Pract; 2022 Mar; 39(2):234-240. PubMed ID: 34893825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Financial sustainability of payment models for office-based opioid treatment in outpatient clinics.
    Hodgkin D; Horgan C; Bart G
    Addict Sci Clin Pract; 2021 Jul; 16(1):45. PubMed ID: 34225785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia.
    Haggerty T; Khodaverdi M; Dekeseredy P; Wood N; Hendricks B; Peklinsky J; Sedney CL
    J Subst Abuse Treat; 2022 May; 136():108687. PubMed ID: 34903397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-month outcomes of the HOPE smartphone application designed to support treatment with medications for opioid use disorder and piloted during an early statewide COVID-19 lockdown.
    Hodges J; Waselewski M; Harrington W; Franklin T; Schorling K; Huynh J; Tabackman A; Otero K; Ingersoll K; Tiouririne NA; Flickinger T; Dillingham R
    Addict Sci Clin Pract; 2022 Mar; 17(1):16. PubMed ID: 35255965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.